Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Junping Shi, M.D.
The Affiliated Hospital of Hangzhou Normal University
Principal Investigator - Vincent Wai-Sun Wong, M.D.
Prince of Wales Hospital, The Chinese University of Hong Kong
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China
- the First Hospital of Jilin University
Changchun, China
- Nanjing Gulou Hospital
Nanjing, China
- Prince of Wales Hospital, the Chinese University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Apr 2025
- Primary completion
- 18 Jun 2026
- Completion
- 30 Sept 2026
- Last update posted
- 7 Jul 2026
- Registered enrollment
- 110
- Registry id
- NCT07024212
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.